Study Shows MicroRNAs can be an Effective Treatment of Drug-Resistant Breast Cancer

MicroRNAs play a crucial regulatory role in drug resistance to a specific drug, a novel approach beneficial for patients with breast cancer who still have a high mortality rate due to secondary recurrence, metastasis, and drug resistance, reveals Professor Ashutosh Kumar's research.

Professor Kumar's research shows nanomedicine's contribution to advancements in nanoparticle-mediated disease treatment. It explores the possibility of co-delivering microRNAs and chemotherapy drugs using an immunoliposome-based delivery system to treat HER2-positive breast cancer. It simultaneously targets the tumor site and sensitises the resistant cells to the drug, aiming for a comprehensive and effective treatment.

Associate Professor at the University's School of Arts and Sciences, Professor Kumar's research on 'Chemotherapy and microRNA Intervention via Liposome-mediated Delivery System targeting HER2: A Comparative Study between miR155/Paclitaxel and miR145/Docetaxel Combinations against Drug-resistant Breast Cancer' has drawn attention from Indian Council of Medical Research.